This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HBV	Not applicable	<p>Rodent studies suggest the addition of Baraclude entecavir to plasmid- and adenoviral vector-based vaccination protocols could help treat chronic HBV infection. In woodchucks chronically infected with woodchuck hepatitis virus (WHV), pretreatment with entecavir followed by injection of a DNA vaccine encoding WHV core antigen led to a more potent antiviral immune response than either treatment alone. Next steps could include developing an analogous vaccine candidate for HBV and evaluating it using the same protocol in combination with entecavir.</p> <p>Bristol-Myers Squibb Co. markets Baraclude, a cyclopentile guanosine nucleoside analog, to treat HBV infection.</p> <p>SciBX 6(28); doi:10.1038/scibx.2013.726 Published online July 25, 2013</p>	Patent and licensing status unavailable	<p>Kosinska, A.D. <i>et al. PLoS Pathog.</i>; published online June 13, 2013; doi:10.1371/journal.ppat.1003391 Contact: Michael Roggendorf, Essen University Hospital, Essen, Germany e-mail: michael.roggendorf@uni-due.de</p>